RECARDIO (REgenerative CARDIOvascular Therapy) is a clinical-stage life science company focusing on therapies for cardiovascular, oncology and infectious diseases. The company is located in San Francisco, California, and is having its operations in USA and Europe.
Regenerative cardiac therapy
RECARDIO’s lead drug dutogliptin, a DPP-IV inhibitor, demonstrated significant effects in activating cardiac regeneration. The clinical program presents a therapeutic platform for cardiovascular patients, with potential of improving heart function, quality of life and survival.
RECARDIO’s global and multicenter Phase 2B study will evaluate the benefit of dutogliptin in combination with G-CSF as an adjunct treatment for patients with acute myocardial infarction.
Being located in the US and Europe, we are committed to develop the regenerative therapies of the future. To support our clinical development, we are continuously looking for expanding our team.